- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 88,080 | 14.06.24 09:10:21 | -0,470 | -0,53% | 87,990 | 88,040 | 88,320 | 88,550 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 952,800 | 14.06.24 08:05:16 | -3,200 | -0,33% | 950,200 | 960,800 | 952,800 | 956,000 |
